Skip to Content

Efalizumab Pregnancy and Breastfeeding Warnings

Efalizumab is also known as: Raptiva

Efalizumab Pregnancy Warnings

Healthcare providers are encouraged to enroll patients who become pregnant while taking efalizumab (or within six weeks of discontinuing the drug) in the Raptiva pregnancy registry.

Efalizumab has been assigned to pregnancy category C by the FDA. Animal studies have not been performed. There are no controlled data in human pregnancy. Efalizumab should only be given during pregnancy when need has been clearly established.

See references

Efalizumab Breastfeeding Warnings

There are no data on the excretion of efalizumab into human milk. Because maternal immunoglobulins are known to be present in the milk of lactating mothers, and animal data suggest the potential for adverse effects from efalizumab in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Raptiva (efalizumab)." Genentech, South San Francisco, CA.
  2. "Multum Information Services, Inc. Expert Review Panel"

References for breastfeeding information

  1. "Product Information. Raptiva (efalizumab)." Genentech, South San Francisco, CA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.